S100A8 and S100A9: DAMPs at the Crossroads Between Innate Immunity, Traditional Risk Factors, and Cardiovascular Disease

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2014 Jan 24

PMID 24453429

Citations 135

Authors

Alexandru Schiopu

Ovidiu S Cotoi

Affiliations

Soon will be listed here.

Abstract

Amplification of innate immune responses by endogenous danger-associated molecular patterns (DAMPs) promotes inflammation. The involvement of S100A8 and S100A9, DAMPs belonging to the S100 calgranulin family, in the pathogenesis of cardiovascular disease is attracting an increasing amount of interest. S100A8 and S100A9 (also termed MRP8 and MRP14) preferentially form the S100A8/A9 heterodimer (MRP8/14 or calprotectin) and are constitutively expressed in myeloid cells. The levels of circulating S100A8/A9 in humans strongly correlate to blood neutrophil counts and are increased by traditional cardiovascular risk factors such as smoking, obesity, hyperglycemia, and dyslipidemia. S100A8/A9 is an endogenous ligand of toll-like receptor 4 (TLR4) and of the receptor for advanced glycation end products (RAGE) and has been shown to promote atherogenesis in mice. In humans, S100A8/A9 correlates with the extent of coronary and carotid atherosclerosis and with a vulnerable plaque phenotype. S100A8/A9 is locally released following myocardial infarction and amplifies the inflammatory responses associated with myocardial ischemia/reperfusion injury. Elevated plasma levels of S100A8/A9 are associated with increased risk of future coronary events in healthy individuals and in myocardial infarction survivors. Thus, S100A8/A9 might represent a useful biomarker and therapeutic target in cardiovascular disease. Importantly, S100A8/A9 blockers have been developed and are approved for clinical testing.

Citing Articles

The sentinels of coronary artery disease: heterogeneous monocytes.

Chen Y, Luo D, Gao R, Wu J, Qiu X, Zou Y Front Immunol. 2025; 16:1428978.

PMID: 40079002 PMC: 11898731. DOI: 10.3389/fimmu.2025.1428978.

RNAseq of peripheral blood mononucleated cells exposed to platelet-rich fibrin and enamel matrix derivatives.

Panahipour L, Kargarpour Z, Mildner M, Kuhtreiber H, Gruber R Sci Rep. 2025; 15(1):3661.

PMID: 39881164 PMC: 11779933. DOI: 10.1038/s41598-025-86791-5.

Identification of Protein Networks and Biological Pathways Driving the Progression of Atherosclerosis in Human Carotid Arteries Through Mass Spectrometry-Based Proteomics.

Kallo G, Zaman K, Potor L, Hendrik Z, Mehes G, Toth C Int J Mol Sci. 2025; 25(24.

PMID: 39769427 PMC: 11728284. DOI: 10.3390/ijms252413665.

Significance of host antimicrobial peptides in the pathogenesis and treatment of acne vulgaris.

Lesiak A, Paprocka P, Wnorowska U, Mankowska A, Krol G, Gluszek K Front Immunol. 2025; 15():1502242.

PMID: 39744637 PMC: 11688235. DOI: 10.3389/fimmu.2024.1502242.

Dysregulated S100A9 Expression Impairs Matrix Deposition in Chronic Wounds.

Franz S, Torregrossa M, Anderegg U, Ertel A, Saalbach A Int J Mol Sci. 2024; 25(18).

PMID: 39337466 PMC: 11432490. DOI: 10.3390/ijms25189980.

References

Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W . The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010; 16(6):713-7. DOI: 10.1038/nm.2150. View

Riva M, Kallberg E, Bjork P, Hancz D, Vogl T, Roth J . Induction of nuclear factor-κB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology. 2012; 137(2):172-82. PMC: 3461398. DOI: 10.1111/j.1365-2567.2012.03619.x. View

Pili R, Haggman M, Stadler W, Gingrich J, Assikis V, Bjork A . Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011; 29(30):4022-8. DOI: 10.1200/JCO.2011.35.6295. View

Peng W, Jian W, Li H, Hou L, Wei Y, Li W . Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2011; 10:41. PMC: 3120649. DOI: 10.1186/1475-2840-10-41. View

Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J . RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008; 29(10):2035-43. PMC: 2556970. DOI: 10.1093/carcin/bgn188. View

Bengtsson A, Sturfelt G, Lood C, Ronnblom L, van Vollenhoven R, Axelsson B . Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging.... Arthritis Rheum. 2011; 64(5):1579-88. DOI: 10.1002/art.33493. View

Viemann D, Barczyk K, Vogl T, Fischer U, Sunderkotter C, Schulze-Osthoff K . MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood. 2006; 109(6):2453-60. DOI: 10.1182/blood-2006-08-040444. View

Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N . Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem. 1991; 266(12):7706-13. View

Passey R, Williams E, Lichanska A, Wells C, Hu S, Geczy C . A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol. 1999; 163(4):2209-16. View

10.

Drechsler M, Megens R, van Zandvoort M, Weber C, Soehnlein O . Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010; 122(18):1837-45. DOI: 10.1161/CIRCULATIONAHA.110.961714. View

11.

Schnekenburger J, Schick V, Kruger B, Manitz M, Sorg C, Nacken W . The calcium binding protein S100A9 is essential for pancreatic leukocyte infiltration and induces disruption of cell-cell contacts. J Cell Physiol. 2008; 216(2):558-67. DOI: 10.1002/jcp.21433. View

12.

Weber C, Noels H . Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11):1410-22. DOI: 10.1038/nm.2538. View

13.

Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A . Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009; 7(4):e97. PMC: 2671563. DOI: 10.1371/journal.pbio.1000097. View

14.

Rahimi F, Hsu K, Endoh Y, Geczy C . FGF-2, IL-1beta and TGF-beta regulate fibroblast expression of S100A8. FEBS J. 2005; 272(11):2811-27. DOI: 10.1111/j.1742-4658.2005.04703.x. View

15.

Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P . Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia. 1998; 41(9):1040-6. DOI: 10.1007/s001250051028. View

16.

Vora A, Bonaca M, Ruff C, Jarolim P, Murphy S, Croce K . Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. J Thromb Thrombolysis. 2012; 34(2):229-34. PMC: 4113032. DOI: 10.1007/s11239-012-0705-y. View

17.

Hobbs J, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C . Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol. 2003; 23(7):2564-76. PMC: 150714. DOI: 10.1128/MCB.23.7.2564-2576.2003. View

18.

Stocca A, OToole D, Hynes N, Hynes S, Mashayekhi K, McGinley L . A role for MRP8 in in stent restenosis in diabetes. Atherosclerosis. 2012; 221(2):325-32. DOI: 10.1016/j.atherosclerosis.2012.01.036. View

19.

McCormick M, Rahimi F, Bobryshev Y, Gaus K, Zreiqat H, Cai H . S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005; 280(50):41521-9. DOI: 10.1074/jbc.M509442200. View

20.

Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J . Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006; 5:6. PMC: 1475836. DOI: 10.1186/1475-2840-5-6. View